ArticleBMC geriatrics2025
Frailty phenotype state transitions among older adults with a history of cancer and diabetes.
Article in BMC geriatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundFrailty is a multi-faceted, aging-related syndrome characterized by reduced physiologic reserve and increased vulnerability to adverse health outcomes. Frailty is dynamic and can improve or worsen over time. Cancer and diabetes are prevalent comorbid conditions in older adults that are independently associated with frailty. Little is known about how the co-occurrence of cancer and diabetes affects frailty in older adults. We investigated how co-occurring cancer and diabetes influence long-term frailty state transitions in older adults.
methodsWe conducted a longitudinal study using Rounds 1-9 of the National Health and Aging Trends Study (2011-2019), a nationally-representative prospective cohort of Medicare beneficiaries (65 + years). We described nine-year transitions across frailty phenotype states (robust, prefrail, frail) and death using a multi-state model, stratifying by cancer and diabetes history in Round 1: neither condition (N = 4,216), cancer only (N = 972), diabetes only (N = 1,434), and both conditions (N = 331). We compared the nine-year incidence of frailty across subgroups using Aalen-Johansen estimators, adjusting for age, race, and gender.
resultsOlder adults without a history of cancer or diabetes had the lowest nine-year mortality (57.5%) compared to those with cancer only (64.4%), diabetes only (65.1%), or both conditions (64.9%). The prevalence of frailty among those alive across time periods was highest in older adults with cancer and diabetes (Round 1 [R1]: 24.7%, R9: 22.3%) and those with diabetes only (R1: 24.0%, R9: 22.4%). The prevalence of frailty was lower in participants with cancer only (R1: 18.0%, R9: 16.3%) and those with neither condition (R1: 13.1%, R9: 15.1%). Among participants who were robust or prefrail at baseline, the nine-year cumulative incidence of frailty was higher among those with diabetes only (52.8%) or diabetes and cancer (54.6%) compared to those with cancer only (41.4%) or neither condition (47.3%).
conclusionsDiabetes and cancer were both associated with an increased frailty prevalence; however, only older adults with diabetes or cooccurring diabetes and cancer had an increased 9-year incidence of frailty relative to older adults without a history of either condition. Future research should explore the underlying mechanisms driving frailty state transitions among chronic disease populations and evaluate targeted interventions to mitigate frailty progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.